HK1064295A1 - Medical aerosol formulations - Google Patents

Medical aerosol formulations

Info

Publication number
HK1064295A1
HK1064295A1 HK04107112.4A HK04107112A HK1064295A1 HK 1064295 A1 HK1064295 A1 HK 1064295A1 HK 04107112 A HK04107112 A HK 04107112A HK 1064295 A1 HK1064295 A1 HK 1064295A1
Authority
HK
Hong Kong
Prior art keywords
aerosol formulations
salts
medical aerosol
medical
dosing
Prior art date
Application number
HK04107112.4A
Other languages
English (en)
Inventor
Rudi Muller-Walz
Carsten Niederlander
Original Assignee
Jagotec Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jagotec Ag filed Critical Jagotec Ag
Publication of HK1064295A1 publication Critical patent/HK1064295A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HK04107112.4A 2001-03-30 2004-09-17 Medical aerosol formulations HK1064295A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH6012001 2001-03-30
CH15272001 2001-08-20
PCT/CH2002/000145 WO2002078671A1 (de) 2001-03-30 2002-03-11 Medizinische aerosolformulierungen

Publications (1)

Publication Number Publication Date
HK1064295A1 true HK1064295A1 (en) 2005-01-28

Family

ID=25737693

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04107112.4A HK1064295A1 (en) 2001-03-30 2004-09-17 Medical aerosol formulations

Country Status (23)

Country Link
US (1) US20040101483A1 (no)
EP (1) EP1372608B1 (no)
JP (1) JP4824267B2 (no)
CN (1) CN100496608C (no)
AT (1) ATE375142T1 (no)
AU (1) AU2002234476B2 (no)
CA (1) CA2442415C (no)
CY (1) CY1107128T1 (no)
CZ (1) CZ301676B6 (no)
DE (1) DE50211045D1 (no)
DK (1) DK1372608T3 (no)
ES (1) ES2292713T3 (no)
HK (1) HK1064295A1 (no)
HU (1) HU229798B1 (no)
NO (1) NO332848B1 (no)
NZ (1) NZ528640A (no)
PL (1) PL207377B1 (no)
PT (1) PT1372608E (no)
RO (1) RO121172B1 (no)
RU (1) RU2294737C2 (no)
SK (1) SK286394B6 (no)
WO (1) WO2002078671A1 (no)
ZA (1) ZA200307161B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
JP2005507881A (ja) 2001-09-17 2005-03-24 グラクソ　グループ　リミテッド 乾燥粉末医薬製剤
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
NZ541168A (en) * 2002-12-10 2008-10-31 Sepracor Inc Levalbuterol salt
GB0316335D0 (en) * 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
JP2009514779A (ja) * 2003-07-11 2009-04-09 グラクソ グループ リミテッド 医薬製剤
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
PT1713473E (pt) 2004-02-06 2013-05-13 Meda Pharma Gmbh & Co Kg Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd
AU2005210084B2 (en) 2004-02-06 2010-06-24 Meda Pharma Gmbh & Co. Kg Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
WO2005074900A2 (en) * 2004-02-06 2005-08-18 Meda Pharma Gmbh & Co. Kg NOVEL COMBINATION OF ANTICHOLINERGIC AND β MIMETICS FOR THE TREATMENT OF RESPIRATORY DISEASES
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
PL1863476T3 (pl) 2005-03-16 2016-07-29 Meda Pharma Gmbh & Co Kg Skojarzenie środków antycholinergicznych i antagonistów receptora leukotrienowego do leczenia chorób układu oddechowego
CA2627982C (en) 2005-11-10 2013-09-10 Nicholas S. Bodor Soft anticholinergic esters
WO2007071313A2 (en) 2005-12-21 2007-06-28 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
AU2012200449B2 (en) * 2005-12-21 2013-07-25 Meda Pharma Gmbh & Co Kg Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases
GB0602897D0 (en) * 2006-02-13 2006-03-22 Jagotec Ag Improvements In Or Relating To Dry Powder Inhaler Devices
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
GB0625303D0 (en) * 2006-12-19 2007-01-24 Jagotec Ag Improvements in and relating to metered dose inhalers
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
AU2015201864A1 (en) * 2009-05-29 2015-04-30 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems
LT2435025T (lt) 2009-05-29 2016-09-26 Pearl Therapeutics, Inc. Veikliosios medžiagos tiekimas per kvėpavimo takus
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation
PT2515855E (pt) 2009-12-23 2014-06-11 Chiesi Farma Spa Terapêutica de combinação para dpoc
SG181870A1 (en) * 2009-12-23 2012-07-30 Chiesi Farma Spa Aerosol formulation for copd
KR101795348B1 (ko) * 2009-12-23 2017-12-01 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 에어로졸 제제
JP5513177B2 (ja) * 2010-03-08 2014-06-04 共同印刷株式会社 湿度インジケータとその製造方法、該製造方法に用いる湿度インジケータ用塗料
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
BR112014008114B1 (pt) 2011-10-11 2022-07-26 Chiesi Farmaceutici S.P.A. Micropartículas cristalinas, formulação farmacêutica, inalador dosimetrado pressurizado, formulação farmacêutica, processo para preparar microparticulas cristalinas e uso de micropartículas cristalinas
CN102362860A (zh) * 2011-10-27 2012-02-29 江阴长风医药科技有限公司 以氢氟烷烃为抛射剂的布地奈德和福莫特罗气雾剂制剂
JP6454323B2 (ja) 2013-03-15 2019-01-16 パール セラピューティクス，インコーポレイテッド 粒子状結晶性材料のコンディショニングのための方法及びシステム
US20190099344A1 (en) * 2016-04-11 2019-04-04 Suven Life Sciences Limited Topical spray formulation of glycopyrrolate

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55361B1 (no) * 1970-09-17 1980-01-08
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
EP0561166A1 (de) * 1992-03-17 1993-09-22 ASTA Medica Aktiengesellschaft Dosieraerosole enthaltend den Wirkstoff D-18024 und verwandte Strukturen
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
JPH06135815A (ja) * 1992-10-30 1994-05-17 Shiseido Co Ltd 経皮吸収抑制組成物
ZA939195B (en) * 1992-12-09 1995-06-08 Boehringer Ingelheim Pharma Stabilized medicinal aerosol solution formulations
DE4321288A1 (de) * 1993-06-26 1995-01-05 Solvay Fluor & Derivate Zusammensetzungen mit chlorfreien, gegebenenfalls wasserstoffhaltigen Fluorkohlenwasserstoffen
EP0731688B1 (en) * 1993-12-02 2003-03-05 Abbott Laboratories Aerosol drug formulations for use with non-cfc propellants
US5589156A (en) * 1994-05-02 1996-12-31 Henry; Richard A. Prilocaine and hydrofluourocarbon aerosol preparations
MY131733A (en) * 1994-12-22 2007-08-30 Astra Ab Aerosol drug formulations
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
JP3707107B2 (ja) * 1995-09-18 2005-10-19 鈴木油脂工業株式会社 薬剤分散液及びその製造方法
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
US6261472B1 (en) * 1996-11-04 2001-07-17 E. I. Du Pont De Nemours And Company Azeotrope-like compositions containing fluoroethane
US6361938B1 (en) * 1996-11-08 2002-03-26 Elan Corporation, Plc Peptides which enhance transport across tissues and methods of identifying and using the same
CA2279648C (en) * 1997-01-30 2007-04-24 Alpenstock Holdings Limited Haemostatic aerosol composition
WO1998034595A1 (de) * 1997-02-05 1998-08-13 Jago Research Ag Medizinische aerosolformulierungen
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
JP4570251B2 (ja) * 1998-07-24 2010-10-27 ヤゴテック アーゲー 医薬用エーロゾル製剤
ATE234604T1 (de) * 1998-08-04 2003-04-15 Jago Res Ag Medizinische aerosolformulierungen
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
BR0015884A (pt) * 2000-05-22 2003-07-08 Chiesi Farma Spa Formulações de soluções farmacêuticas estáveis para inaladores de dose medida pressurizados
WO2002011711A2 (en) * 2000-08-04 2002-02-14 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
AU2002222118A1 (en) * 2000-11-30 2002-06-11 Vectura Limited Pharmaceutical compositions for inhalation
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
MEP30108A (en) * 2002-03-01 2010-06-10 Chiesi Farmaceutici S P Formoterol superfine formulation
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0323685D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) * 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0918150D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved formulations
GB0918149D0 (en) * 2009-10-16 2009-12-02 Jagotec Ag Improved medicinal aerosol formulation

Also Published As

Publication number Publication date
CN100496608C (zh) 2009-06-10
ZA200307161B (en) 2005-01-26
RU2294737C2 (ru) 2007-03-10
AU2002234476B2 (en) 2006-04-27
ATE375142T1 (de) 2007-10-15
WO2002078671A1 (de) 2002-10-10
CN1499958A (zh) 2004-05-26
EP1372608B1 (de) 2007-10-10
PL207377B1 (pl) 2010-12-31
DE50211045D1 (de) 2007-11-22
JP4824267B2 (ja) 2011-11-30
CY1107128T1 (el) 2012-10-24
EP1372608A1 (de) 2004-01-02
AU2002234476C1 (en) 2002-10-15
PL362797A1 (en) 2004-11-02
HUP0401250A3 (en) 2008-04-28
HU229798B1 (en) 2014-07-28
HUP0401250A2 (hu) 2004-11-29
CZ20032915A3 (en) 2004-06-16
RO121172B1 (ro) 2007-01-30
ES2292713T3 (es) 2008-03-16
DK1372608T3 (da) 2007-12-27
US20040101483A1 (en) 2004-05-27
CA2442415A1 (en) 2002-10-10
NO20034323L (no) 2003-09-26
CA2442415C (en) 2010-07-20
NO332848B1 (no) 2013-01-21
JP2004525148A (ja) 2004-08-19
CZ301676B6 (cs) 2010-05-19
SK286394B6 (sk) 2008-09-05
RU2003131676A (ru) 2005-02-10
PT1372608E (pt) 2008-01-04
NO20034323D0 (no) 2003-09-26
SK13342003A3 (sk) 2004-08-03
NZ528640A (en) 2004-06-25

Similar Documents

Publication Publication Date Title
HK1064295A1 (en) Medical aerosol formulations
DE60207198D1 (de) Transplantate für die wiederherstellung von osteochondralen schäden
ATE373422T1 (de) Mikroemulsionbildende herbizidkonzentrate, mikroemulsionen und verfahren
ATE302616T1 (de) Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe
HK1036931A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients.
SG127738A1 (en) Heterocyclic compounds based on n6-substituted adenine, methods of their preparation, their use for preparation of drugs, pharmaceutical preparations containing these compounds
NZ527157A (en) Compositions for delivering bisphosphonates
DK1102579T3 (da) Medicinske aerosolformuleringer
EA200800927A1 (ru) КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ
WO2007060104A3 (de) Aerosolformulierung für die inhalation enthaltend ein anticholinergikum
ATE275393T1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
MXPA05013637A (es) Inhibidores gsk-3 y usos de los mismos.
CA2481848A1 (en) Active ingredient particles carrying clopidogrel or a salt thereof, their use and method of preparation
WO2007060108A3 (de) Aerosolformulierung für die inhalation enthaltend ein anticholinergikum
ATE291424T1 (de) Katechin und quercetin zur pharmazeutischen oder diätetischen verwendung
PL1868631T3 (pl) Zastosowanie związków indukujących syntezę białek SIRT przy lub dla otrzymywania kompozycji kosmetycznej lub farmaceutycznej
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
TNSN04034A1 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
UY27373A1 (es) Formulaciones de interferón beta-humano
BR0207725A (pt) Promotores do crescimento e/ou da diferenciação de células-tronco hematopoiéticas e/ou progenitores hematopoiéticos
DE60308899D1 (de) Quaternäre verbindungen enthaltend propolis als wirkstoff
WO2001001975A3 (en) Hypoestoxides, derivatives and agonists thereof for use as antiparasitic agents
BR0011845A (pt) Complexo farmacêutico
HK1065305A1 (en) Substituted 4-aminocyclohexanol derivatives
BRPI0507144A (pt) formulações em pó

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20180311